Vertex Pharmaceuticals to acquire Alpine Immune Sciences for $4.9 billion

Vertex Pharmaceuticals has agreed to acquire Alpine Immune Sciences for $4.9 billion in cash, bolstering its portfolio on kidney diseases as deals in biotechnology continue to heat up.

Previous post Boeing needs to focus on solutions, not shareholders
Next post Honest Co. shares dip 7% after Jessica Alba steps down from company she founded